BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

765 related articles for article (PubMed ID: 26497680)

  • 1. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
    Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.
    Lin TC; Tsai LH; Chou MC; Chen CY; Lee H
    Tumour Biol; 2016 Mar; 37(3):4017-23. PubMed ID: 26482622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoplasmic, but not nuclear Nrf2 expression, is associated with inferior survival and relapse rate and response to platinum-based chemotherapy in non-small cell lung cancer.
    Chen MJ; Lin PL; Wang L; Cheng YM; Chen CY; Lee H
    Thorac Cancer; 2020 Jul; 11(7):1904-1910. PubMed ID: 32394538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway.
    Chen PM; Cheng YW; Wu TC; Chen CY; Lee H
    Free Radic Biol Med; 2015 Feb; 79():127-37. PubMed ID: 25499851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression.
    Wu DW; Wu TC; Wu JY; Cheng YW; Chen YC; Lee MC; Chen CY; Lee H
    Oncogene; 2014 Aug; 33(35):4385-95. PubMed ID: 24096476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2.
    Yin Y; Liu H; Xu J; Shi D; Zhai L; Liu B; Wang L; Liu G; Qin J
    Oncol Rep; 2018 Dec; 40(6):3479-3488. PubMed ID: 30542710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-29b-3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO-1 signaling pathway in non-small cell lung cancer.
    Sun Z; Ren M; Niu J; Tang G; Li Y; Kong F; Song X
    Environ Toxicol; 2024 Jul; 39(7):3956-3966. PubMed ID: 38587027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
    Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
    Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs].
    Wang JQ; Du ZW; Gao XF; Wu M; Zhang YC; Pan Y; Wang Q; Zhang GZ
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):191-7. PubMed ID: 23856142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells.
    Ikuta K; Takemura K; Kihara M; Naito S; Lee E; Shimizu E; Yamauchi A
    Oncol Rep; 2005 Jun; 13(6):1229-34. PubMed ID: 15870947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Gregorc V; Ludovini V; Pistola L; Darwish S; Floriani I; Bellezza G; Sidoni A; Cavaliere A; Scheibel M; De Angelis V; Bucciarelli E; Tonato M
    Lung Cancer; 2003 Jan; 39(1):41-8. PubMed ID: 12499093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
    Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
    Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p21 and bcl-2 proteins and p53 mRNA in surgically resected preparations of non-small cell lung cancer (stage IIIA) after etoposide and cisplatin chemotherapy.
    Mańdziuk S; Dudzisz-Sledź M; Rybacka-Chabros B; Zdunek M; Jakubowicz-Klecha A; Korobowicz E; Milanowski J; Wojcierowski J
    Folia Histochem Cytobiol; 2001; 39 Suppl 2():175-6. PubMed ID: 11820594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.
    Tian Y; Zhang J; Yan S; Qiu L; Li Z
    Lung Cancer; 2012 Jun; 76(3):416-22. PubMed ID: 22137560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
    Jeong SH; Jung JH; Han JH; Kim JH; Choi YW; Lee HW; Kang SY; Hwang YH; Ahn MS; Choi JH; Oh YT; Chun M; Kang S; Park KJ; Hwang SC; Sheen SS
    Lung Cancer; 2010 May; 68(2):288-94. PubMed ID: 19560836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.